177 related articles for article (PubMed ID: 32681462)
1. Pituitary neuroendocrine tumors and differentiated thyroid cancer: do metabolic and inflammatory risk factors play roles?
Cortês Nascimento G; de Araujo Cortês Nascimento AGP; de Maria Ribeiro Veiga Parente C; Rodrigues VP; de Sousa Azulay RS; de Carvalho Rocha VC; da Silva Pereira Damianse S; Magalhães M; Dos Santos Faria M; Gomes MB
J Endocrinol Invest; 2021 Apr; 44(4):735-744. PubMed ID: 32681462
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of thyroid cancer in patients with acromegaly and non-growth hormone secreting pituitary adenomas: A prospective cross-sectional study.
Spricido IY; Feckinghaus CM; Silva RHM; Mesa Junior CO; Boguszewski CL
Growth Horm IGF Res; 2021 Feb; 56():101378. PubMed ID: 33486451
[TBL] [Abstract][Full Text] [Related]
3. Differentiated thyroid carcinoma in sporadic and familial presentations of acromegaly: A case series.
Rogozinski A; Daly AF; Reyes A; Furioso A; Beckers A; Lowenstein A
Ann Endocrinol (Paris); 2020 Oct; 81(5):482-486. PubMed ID: 32822652
[TBL] [Abstract][Full Text] [Related]
4. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma.
Rezzónico JN; Rezzónico M; Pusiol E; Pitoia F; Niepomniszcze H
Metab Syndr Relat Disord; 2009 Aug; 7(4):375-80. PubMed ID: 19320560
[TBL] [Abstract][Full Text] [Related]
5. Relationship between insulin resistance and thyroid cancer in Chinese euthyroid subjects without conditions affecting insulin resistance.
Xu N; Liu H; Wang Y; Xue Y
BMC Endocr Disord; 2022 Mar; 22(1):58. PubMed ID: 35255873
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk factors of cancers in acromegaly: a Chinese single-center retrospective study.
Xiao T; Jiao R; Yang S; Wang Y; Bai X; Zhou J; Li R; Wang L; Yang H; Yao Y; Deng K; Gong F; Pan H; Duan L; Zhu H
Endocrine; 2023 Nov; 82(2):368-378. PubMed ID: 37442901
[TBL] [Abstract][Full Text] [Related]
7. Is the incidence of differentiated thyroid cancer increased in patients with thyrotropin-secreting adenomas? Report of three cases from a large consecutive series.
Perticone F; Pigliaru F; Mariotti S; Deiana L; Furlani L; Mortini P; Losa M
Thyroid; 2015 Apr; 25(4):417-24. PubMed ID: 25647054
[TBL] [Abstract][Full Text] [Related]
8. Thyroid cancer in patients with acromegaly: a case-control study.
dos Santos MC; Nascimento GC; Nascimento AG; Carvalho VC; Lopes MH; Montenegro R; Montenegro R; Vilar L; Albano MF; Alves AR; Parente CV; dos Santos Faria M
Pituitary; 2013 Mar; 16(1):109-14. PubMed ID: 22527615
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study.
Gasperi M; Martino E; Manetti L; Arosio M; Porretti S; Faglia G; Mariotti S; Colao AM; Lombardi G; Baldelli R; Camanni F; Liuzzi A;
J Endocrinol Invest; 2002 Mar; 25(3):240-5. PubMed ID: 11936466
[TBL] [Abstract][Full Text] [Related]
10. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
11. Investigation of insulin resistance gene polymorphisms in patients with differentiated thyroid cancer.
Akker M; Güldiken S; Sipahi T; Palabıyık O; Tosunoğlu A; Çelik Ö; Tunçbilek N; Sezer A; Süt N
Mol Biol Rep; 2014 May; 41(5):3541-7. PubMed ID: 24504452
[TBL] [Abstract][Full Text] [Related]
12. Abnormal Glucose Metabolism Parameters and the Aggressiveness of Differentiated Thyroid Carcinoma: A Hospital-Based Cross-Section Study in China.
Zhao J; Tian Y; Jia Z; Yao J; Liao L; Dong J
Front Endocrinol (Lausanne); 2022; 13():806349. PubMed ID: 35299970
[TBL] [Abstract][Full Text] [Related]
13. Disease Activity May Not Affect the Prognosis of Coexisting Thyroid Cancer in Acromegalic Patients.
Gul N; Soyluk O; Dogansen SC; Kurtulmus N; Yarman S
Exp Clin Endocrinol Diabetes; 2020 Sep; 128(9):567-572. PubMed ID: 31185505
[TBL] [Abstract][Full Text] [Related]
14. HOMA-IR in acromegaly: a systematic review and meta-analysis.
Biagetti B; Aulinas A; Casteras A; Pérez-Hoyos S; Simó R
Pituitary; 2021 Apr; 24(2):146-158. PubMed ID: 33085039
[TBL] [Abstract][Full Text] [Related]
15. The role of metabolic setting in predicting the risk of early tumour relapse of differentiated thyroid cancer (DTC).
Mele C; Caputo M; Samà MT; Bullara V; Mauri MG; Prodam F; Aimaretti G; Pagano L; Marzullo P
Eur J Clin Nutr; 2020 Jul; 74(7):1038-1046. PubMed ID: 32518296
[TBL] [Abstract][Full Text] [Related]
16. Duodenal adenocarcinoma with neuroendocrine features in a patient with acromegaly and thyroid papillary adenocarcinoma: a unique combination of endocrine neoplasia.
Kato K; Takeshita Y; Misu H; Ishikura K; Kakinoki K; Sawada-Kitamura S; Kaneko S; Takamura T
Endocr J; 2012; 59(9):791-6. PubMed ID: 22673565
[TBL] [Abstract][Full Text] [Related]
17. "Is there any association between insulin resistance and thyroid cancer? : A case control study".
Balkan F; Onal ED; Usluogullari A; Tuzun D; Ozdemir D; Inancli SS; Ersoy R; Cakir B
Endocrine; 2014 Feb; 45(1):55-60. PubMed ID: 23564559
[TBL] [Abstract][Full Text] [Related]
18. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
19. Circulating adipokines and metabolic setting in differentiated thyroid cancer.
Mele C; Samà MT; Bisoffi AA; Caputo M; Bullara V; Mai S; Walker GE; Prodam F; Marzullo P; Aimaretti G; Pagano L
Endocr Connect; 2019 Jul; 8(7):997-1006. PubMed ID: 31252407
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomic Classification of Pituitary Neuroendocrine Tumors Causing Acromegaly.
Rymuza J; Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Nyc A; Baluszek S; Zieliński G; Kunicki J; Bujko M
Cells; 2022 Nov; 11(23):. PubMed ID: 36497102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
